Mammoth Biosciences has raised $45 million in an oversubscribed Series B financing with the goal of expanding beyond CRISPR-based disease detection—including a collaboration targeting 2019-nCoV coronavirus—towards offerings that apply the company’s platform to gene editing and next-generation therapeutics . . .

Get GEN Edge Today!

The post Mammoth Pursues Coronavirus Partnership as It Grows CRISPR Ambitions appeared first on GEN – Genetic Engineering and Biotechnology News.